Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 6112 | 11.27 |
09:34 ET | 200 | 11.34 |
09:36 ET | 2700 | 11.315 |
09:38 ET | 2110 | 11.255 |
09:39 ET | 1400 | 11.25 |
09:41 ET | 4598 | 11.145 |
09:43 ET | 908 | 11.14 |
09:45 ET | 3500 | 11.155 |
09:48 ET | 1117 | 11.185 |
09:50 ET | 1005 | 11.25 |
09:52 ET | 785 | 11.305 |
09:54 ET | 630 | 11.41 |
09:56 ET | 4402 | 11.39 |
09:57 ET | 1341 | 11.39 |
09:59 ET | 2000 | 11.41 |
10:01 ET | 2813 | 11.49 |
10:03 ET | 2596 | 11.56 |
10:06 ET | 1415 | 11.54 |
10:08 ET | 3193 | 11.5 |
10:10 ET | 600 | 11.53 |
10:12 ET | 1521 | 11.62 |
10:15 ET | 814 | 11.61 |
10:17 ET | 835 | 11.6 |
10:19 ET | 1955 | 11.57 |
10:21 ET | 3491 | 11.54 |
10:24 ET | 405 | 11.55 |
10:26 ET | 2858 | 11.45 |
10:28 ET | 300 | 11.44 |
10:30 ET | 3275 | 11.48 |
10:32 ET | 570 | 11.48 |
10:35 ET | 850 | 11.57 |
10:37 ET | 12720 | 11.51 |
10:39 ET | 1000 | 11.5358 |
10:42 ET | 753 | 11.53 |
10:44 ET | 1057 | 11.5001 |
10:46 ET | 200 | 11.55 |
10:48 ET | 800 | 11.545 |
10:50 ET | 400 | 11.55 |
10:51 ET | 829 | 11.55 |
10:53 ET | 100 | 11.56 |
10:55 ET | 200 | 11.525 |
10:57 ET | 1600 | 11.51 |
11:00 ET | 403 | 11.49 |
11:02 ET | 4232 | 11.385 |
11:04 ET | 300 | 11.37 |
11:06 ET | 200 | 11.37 |
11:08 ET | 1175 | 11.41 |
11:09 ET | 100 | 11.41 |
11:11 ET | 100 | 11.42 |
11:13 ET | 430 | 11.44 |
11:15 ET | 600 | 11.49 |
11:18 ET | 2100 | 11.46 |
11:20 ET | 1200 | 11.5 |
11:22 ET | 814 | 11.48 |
11:24 ET | 2406 | 11.47 |
11:26 ET | 300 | 11.45 |
11:27 ET | 1616 | 11.44 |
11:29 ET | 300 | 11.415 |
11:31 ET | 200 | 11.4 |
11:33 ET | 399 | 11.4 |
11:36 ET | 300 | 11.385 |
11:38 ET | 1000 | 11.385 |
11:40 ET | 2540 | 11.44 |
11:42 ET | 3200 | 11.46 |
11:44 ET | 4905 | 11.475 |
11:47 ET | 2315 | 11.51 |
11:49 ET | 951 | 11.51 |
11:51 ET | 400 | 11.515 |
11:54 ET | 521 | 11.51 |
11:58 ET | 5111 | 11.495 |
12:00 ET | 949 | 11.44 |
12:02 ET | 500 | 11.44 |
12:03 ET | 3278 | 11.46 |
12:05 ET | 1309 | 11.44 |
12:07 ET | 2235 | 11.44 |
12:09 ET | 2251 | 11.435 |
12:12 ET | 1700 | 11.43 |
12:16 ET | 2114 | 11.44 |
12:18 ET | 5575 | 11.43 |
12:20 ET | 4251 | 11.42 |
12:21 ET | 2582 | 11.43 |
12:23 ET | 3067 | 11.47 |
12:25 ET | 300 | 11.47 |
12:27 ET | 100 | 11.49 |
12:30 ET | 1962 | 11.45 |
12:32 ET | 6907 | 11.415 |
12:34 ET | 1150 | 11.42 |
12:36 ET | 1294 | 11.44 |
12:38 ET | 7020 | 11.45 |
12:39 ET | 1028 | 11.435 |
12:41 ET | 1090 | 11.44 |
12:43 ET | 3569 | 11.4612 |
12:45 ET | 200 | 11.47 |
12:48 ET | 200 | 11.47 |
12:50 ET | 2918 | 11.425 |
12:52 ET | 300 | 11.44 |
12:54 ET | 1809 | 11.43 |
12:56 ET | 2495 | 11.43 |
12:57 ET | 100 | 11.44 |
12:59 ET | 3470 | 11.45 |
01:01 ET | 1791 | 11.4 |
01:03 ET | 450 | 11.37 |
01:06 ET | 1813 | 11.44 |
01:08 ET | 700 | 11.43 |
01:10 ET | 341 | 11.44 |
01:14 ET | 1162 | 11.45 |
01:15 ET | 433 | 11.46 |
01:17 ET | 1204 | 11.47 |
01:19 ET | 900 | 11.45 |
01:24 ET | 1750 | 11.44 |
01:26 ET | 2487 | 11.44 |
01:28 ET | 1122 | 11.45 |
01:30 ET | 400 | 11.46 |
01:32 ET | 4223 | 11.44 |
01:33 ET | 941 | 11.44 |
01:35 ET | 200 | 11.45 |
01:37 ET | 601 | 11.46 |
01:39 ET | 11455 | 11.5 |
01:42 ET | 1130 | 11.4932 |
01:44 ET | 14255 | 11.45 |
01:46 ET | 354 | 11.4499 |
01:48 ET | 4792 | 11.45 |
01:50 ET | 425 | 11.47 |
01:51 ET | 916 | 11.445 |
01:53 ET | 2561 | 11.44 |
01:55 ET | 3535 | 11.44 |
01:57 ET | 200 | 11.45 |
02:00 ET | 935 | 11.47 |
02:02 ET | 2979 | 11.455 |
02:04 ET | 315 | 11.45 |
02:06 ET | 200 | 11.455 |
02:08 ET | 1621 | 11.48 |
02:09 ET | 100 | 11.48 |
02:11 ET | 100 | 11.485 |
02:13 ET | 5241 | 11.45 |
02:15 ET | 1100 | 11.46 |
02:18 ET | 2035 | 11.46 |
02:20 ET | 300 | 11.45 |
02:22 ET | 612 | 11.45 |
02:24 ET | 3825 | 11.46 |
02:26 ET | 3897 | 11.43 |
02:27 ET | 1710 | 11.45 |
02:29 ET | 3248 | 11.44 |
02:31 ET | 2699 | 11.43 |
02:33 ET | 3648 | 11.44 |
02:36 ET | 450 | 11.45 |
02:38 ET | 6253 | 11.42 |
02:40 ET | 1771 | 11.44 |
02:42 ET | 2476 | 11.46 |
02:44 ET | 600 | 11.46 |
02:45 ET | 1425 | 11.45 |
02:47 ET | 5167 | 11.46 |
02:49 ET | 850 | 11.47 |
02:51 ET | 200 | 11.46 |
02:54 ET | 573 | 11.475 |
02:56 ET | 2676 | 11.48 |
02:58 ET | 600 | 11.48 |
03:00 ET | 2500 | 11.49 |
03:02 ET | 400 | 11.5 |
03:03 ET | 1300 | 11.53 |
03:05 ET | 1013 | 11.55 |
03:07 ET | 1240 | 11.6 |
03:09 ET | 1816 | 11.66 |
03:12 ET | 2361 | 11.63 |
03:14 ET | 100 | 11.64 |
03:16 ET | 700 | 11.659 |
03:18 ET | 1282 | 11.65 |
03:20 ET | 1719 | 11.65 |
03:21 ET | 1056 | 11.63 |
03:23 ET | 1025 | 11.64 |
03:25 ET | 2600 | 11.7 |
03:27 ET | 3185 | 11.73 |
03:30 ET | 19408 | 11.77 |
03:32 ET | 3698 | 11.74 |
03:34 ET | 1600 | 11.808 |
03:36 ET | 3662 | 11.81 |
03:38 ET | 5870 | 11.85 |
03:39 ET | 1821 | 11.87 |
03:41 ET | 6203 | 11.84 |
03:43 ET | 1500 | 11.84 |
03:45 ET | 3254 | 11.849 |
03:48 ET | 2266 | 11.82 |
03:50 ET | 647 | 11.82 |
03:52 ET | 4902 | 11.86 |
03:54 ET | 8928 | 11.77 |
03:56 ET | 7677 | 11.72 |
03:57 ET | 14138 | 11.71 |
03:59 ET | 29598 | 11.65 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 395.4M | -3.3x | --- |
LENZ Therapeutics Inc | 400.9M | -1.0x | --- |
Terns Pharmaceuticals Inc | 388.1M | -5.0x | --- |
ACELYRIN Inc | 409.0M | -1.6x | --- |
Fibrobiologics Inc | 375.6M | -11.6x | --- |
Neurogene Inc | 416.8M | -6.9x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $395.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.